Announcements Trials
Browse Landscape

Phase

Phase 4 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 7Prostatic Neoplasms 2Liver Neoplasms 2Colorectal Neoplasms 2Neuroendocrine Tumors 1Digestive System Diseases 1Breast Neoplasms 1

Interventions

Sorafenib 61Bevacizumab 42Oxaliplatin 24Doxorubicin 22Radiosurgery 20Gemcitabine 20Fluorouracil 20Nivolumab 19durvalumab 18Radiofrequency Ablation 18pembrolizumab 17Capecitabine 17lenvatinib 16Cisplatin 16atezolizumab 13Leucovorin 13Radiotherapy 11tremelimumab 10Cyclophosphamide 10Carboplatin 10Irinotecan 9Ipilimumab 9Drug Therapy 9Everolimus 8Cryosurgery 8toripalimab 7fludarabine 7Sunitinib 7Chemotherapy, Adjuvant 7Melphalan 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Liver Neoplasms × gadolinium ethoxybenzyl DTPA × Clear all
NCT04288323 2026-02-12

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

University of California, San Diego

Phase 4 Completed
79 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03215355 2021-01-27

Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium

Nova Scotia Health Authority

Phase 4 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡